Duke Startup restor3d Raises $23M to Expand 3D Printed Personalized Solutions for Musculoskeletal Surgery and Develop Machine Learning Enabled Design Tools
DURHAM, N.C., April 5, 2022–(BUSINESS WIRE)–restor3d, a leading medical device company and 3D printing manufacturer, has raised $23 million to expand the delivery of 3D printed personalized surgical solutions across multiple musculoskeletal specialties and to…
Venture Day 2022 Highlights Early-stage Life-science Companies in the Triangle
From left to right: Vivian Doelling, Vice President for Investments and Emerging Company Development at NC Biotechnology Center, Jeff Welch, Director of Duke New Ventures, Mireya McKee, Director of UNC’s KickStart Venture Services, and Michael…
Media Coverage: Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health
By Alix Ventures BIOS: Nucleus of Life Science Innovation Overview Behind every transformative technology is a team of brilliant scientists and researchers. Academic research in particular is a driving force for technological innovation. Here, we have…
A Gel That Regrows the Brain
Tatiana Segura, professor of biomedical engineering, is changing outcomes for stroke patients. By Duke Today’s Staff, March 2, 2022 Tatiana Segura has discovered a way to modify biomaterials—such as polymers that are found naturally in living…
Complex Chronic Disease Startup ZealCare Launched: Announcing New Board Members
The personalized, integrative chronic disease management company has recruited industry innovators Maureen O’Connor, Steve Nelson, Marcus Osborne, and Christopher O’Connor, MD Research Triangle Park, NC, February 4, 2022 – ZealCare today announced its emergence from…
Duke Leading Efforts to Develop Pan-Coronavirus Vaccine
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Duke Human Vaccine Institute (DHVI) $17.5 million in October 2021 to proceed with development of a next-generation “pan-coronavirus” vaccine, one that protects against…
Isolere Bio Enters into Research Collaboration Agreement with Oxford Biomedica to Develop Enabling Manufacturing Technology for Lentiviral Vectors
DURHAM, NC and OXFORD, UK — January 31, 2022 – Isolere Bio, a bioprocessing company that provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics and Oxford Biomedica (LSE:OXB), a leading gene and…
Kriya Expands Gene Therapy Pipeline and Establishes its Rare Disease Therapeutic Area Division with the Acquisition of Warden Bio
Portfolio includes five investigational gene therapy programs for glycogen storage disorders that have no existing FDA-approved treatments available Warden Bio Co-Founder Kunal Kishnani joins as President of Kriya’s Rare Disease Division and will lead its…
Precision Molecular Inc. Executes License for Exclusive Rights to an Astatine-211-Labeled Radiopharmaceutical Inhibitor of Prostate-Specific Membrane Antigen for Prostate Cancer Therapeutics
Currently in IND-enabling studies, PMI21 is expected to advance into clinical trials in patients with metastatic prostate cancer in 2022 Astatine-211 labelling offers important advantages in terms of potency and safety of radiopharmaceuticals as…